All News

Sharing concrete steps and suggestions can help ease the way for patients looking to transition to a more healthful lifestyle.

Health care professionals all agree that a healthy diet is the foundation of cardiovascular and cardiometabolic health, but follow-through on the population level is lacking.

Check out this recap of articles published on our sister sites during the past week.

GLP-1 therapies are being evaluated to treat cardiovascular and kidney diseases in individuals with overweight or obesity.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

These therapies are highly beneficial, but can come with a host of gastrointestinal adverse effects that patients may not be prepared to manage alone.

Some patients may have difficulty managing the gastrointestinal adverse effects associated with GLP-1 therapies.

Losing even 5% of body weight can improve comorbid conditions and other health complications for individuals with overweight and obesity.

Check out important updated from the FDA for the week of July 29.

The technology from Diakonos Oncology initiates a natural immune response that targets and eliminates cancer cells by activating cytotoxic TH1 cell signaling pathways.

Afami-cel is the first new treatment for synovial sarcoma in more than 10 years, ending a long-standing therapeutic gap.

Liraglutide slowed the loss of volume in critical brain regions and cognitive decline in patients with mild Alzheimer's dementia.

Pharmacists should be knowledgeable about the symptoms of chemical peel irritation to effectively advise patients.

In 3 Phase 3 trials, elinzanetant reduced the frequency and severity of moderate to severe vasomotor symptoms, and improved sleep disturbances.

Researchers aimed to address the association of all-cause dementia risk and 3 separate chronicities of anxiety.

Anisha Patel, PharmD, a pharmacist turned podcast host, shares insights on leveraging all the opportunities pharmacy has to offer to build a diverse and rewarding career.

Catch up on important immunization news from the month of July.

The investigational oral, selective NaV1.8 pain signal inhibitor from Vertex Pharmaceuticals demonstrated a favorable benefit/risk profile in 3 phase 3 trials.

Researchers aimed to address the change in trust individuals exhibited regarding US physicians and hospitals during the COVID-19 pandemic.

Catch up on important diabetes news from the month of July.

Catch up on important pain management news from the month of July.

Recent studies on dry eye disease examined the efficacy of Vitamin D, platelet-rich plasma as a treatment option, and associations with certain systemic medications.

CVS Caremark and the State of Illinois settled a lawsuit due to the company’s failure to pay contracted rebates.

The new FDA-approved presentation will be the company’s third 505(b)(2) injectable added in 2024, expected to launch in the third quarter.

Catch up on important dermatology news from the month of July.

Recent research on COVID-19 examined cognitive loss after an infection, how pandemic restrictions impacted excess deaths, and the increase in physicians experiencing PTSD.

Researchers analyzed the prominence of opioid and methadone prescriptions for hospitalized newborns with substantial morbidities.

Check out this list of our top 10 most read stories from July 2024.